Evidence map›Paper›PMID 41770818›Full record

ArticlePLoS pathogens2026

HIV-1 Vpr is targeted for degradation by autophagy.

Yuexuan Chen, Susanne Klute, Anju Bansal, Konstantin Maria Johannes Sparrer, Ruth Serra-Moreno

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuexuan ChenDepartment of Microbiology and Immunology. University of Rochester Medical Center. Rochester, New York, United States of America.
Susanne KluteInstitute of Molecular Virology, University of Ulm, Ulm, Germany.
Anju BansalDepartment of Medicine, Infectious Diseases, Heersink School of Medicine. University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Konstantin Maria Johannes SparrerInstitute of Molecular Virology, University of Ulm, Ulm, Germany.
Ruth Serra-MorenoDepartment of Microbiology and Immunology. University of Rochester Medical Center. Rochester, New York, United States of America.ORCID https://orcid.org/0000-0002-1923-6414

Funding

New insights into the interplay between HIV and the autophagy machineryR01AI155012 · NIAID · UNIVERSITY OF ROCHESTER · PI SERRA MORENO, RUTH · 2021 to 2025
$1.9M
NIAID NIH HHS R01 AI155012
6 · The paper itself

Abstract

Autophagy is part of the innate immune arsenal to fight viruses, including HIV-1. We previously reported that HIV-1 Gag is targeted for autophagy-mediated degradation. Here, we identify HIV-1 Vpr, an important virulence factor, as an autophagy target in HIV-1 NL4-3, a lab adapted molecular clone. Notably, Vpr proteins from a collection of transmitted/founder viruses (TFVs) were resistant to autophagy. Based on this observation, we identified residues at positions 37, 45, 77, 83-86, 93-94 in NL4-3 Vpr as responsible for its susceptibility to autophagy. Importantly, differences between NL4-3 and TFV Vpr proteins at these positions impact their interaction with the autophagy receptors NDP52, SQSTM1/p62 and TAX1BP1. By engineering NL4-3 molecular clones harboring either autophagy-sensitive or -resistant vpr, we found that in 2D and 3D in vitro systems virus spread was significantly reduced for the virus carrying autophagy-sensitive Vpr. In conclusion, our study identifies Vpr as a novel autophagy target and suggests that Vpr susceptibility to autophagy impacts HIV-1 spread.

Indexed as

AutophagyHIV-1HIV Infectionsvpr Gene Products, Human Immunodeficiency VirusHumansvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1

Identifiers

PMID41770818
PMCPMC12970978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.